Aprocin 500 mg 10 Pcs
Aprocin 500 mg 10 Pcs Original price was: 150.50৳ .Current price is: 142.98৳ .
Back to products
Aristomox Powder for Suspension
Aristomox Powder for Suspension Original price was: 45.00৳ .Current price is: 42.75৳ .

Aprocin 750 mg 10 Pcs

SKU: 5872

Manufacturer: Aristopharma Limited

Generic: Ciprofloxacin 750 mg Tablet

Type: Tablet

Pack Size: 10 Pcs

Apple Shopping Event

Hurry and get discounts on all Apple devices up to 20%

Sale_coupon_15

Original price was: 180.59৳ .Current price is: 171.56৳ .

Description

Tablet Manufacturer/Distributor: Aristopharma Limited Generic Name: Ciprofloxacin 750 mg Tablet

Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below.

Uncomplicated Urinary Tract Infections (Acute Cystitis): Ciprofloxacin is indicated for the treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli, Proteus mirabilis, Enterococcus faecalis, or Staphylococcus saprophyticus.

Because fluoroquinolones, including Ciprofloxacin, have been associated with serious adverse reactions and for some patients uncomplicated UTI (acute cystitis) is self-limiting, reserve Ciprofloxacin for treatment of uncomplicated UTIs (acute cystitis) in patients who have no alternative treatment options.

Complicated Urinary Tract Infections, And Acute Uncomplicated Pyelonephritis: Ciprofloxacin is indicated for the treatment of complicated urinary tract infections (cUTI) caused by Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Proteus mirabilis, or Pseudomonas aeruginosa and acute uncomplicated pyelonephritis(AUP) caused by Escherichia coli.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin and other antibacterialdrugs, Ciprofloxacin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.